

Datasheet for 600-401-G99**IL-23 Antibody****Overview**

Description:	Anti-IL-23 (RABBIT) Antibody - 600-401-G99
Item No.:	600-401-G99
Size:	100 µg
Applications:	ELISA, IF, IHC, WB
Reactivity:	Human, Mouse
Host Species:	Rabbit

Product Details

Background:	IL-23 antibody detects human IL-23. Like interleukin-27 (IL-27), IL-23 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the IL-12p40 subunit and a novel p19 subunit. IL-23 is secreted by activated dendritic cells, macrophages, and monocytes. Its biological activities include enhancing the proliferation of memory T cells and the production of IFN-gamma, IL-12, and TNF-alpha from activated T cells, and can stimulate macrophages to produce TNF-alpha and nitric oxide. It has also been shown to possess potent anti-tumor and anti-metastatic activity in mouse models of cancer, suggesting a potential role for IL-23 in therapeutic treatment of cancer. Anti-IL-23 antibodies are ideal for investigators involved in cytokine and growth factors and cancer research.
Synonyms:	SGRF, IL23A, Interleukin-23 subunit alpha, IL-23 subunit alpha, IL-23-A, Interleukin-23 subunit p19, IL-23p19
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	IL23A
Reactivity:	Human, Mouse
Immunogen Type:	Conjugated Peptide

Immunogen:	IL-23 Antibody was produced from whole rabbit serum prepared by repeated immunizations with a peptide near the c-terminus of human IL-23.
Purity/Specificity:	Anti-IL-23 Antibody was affinity purified from monospecific antiserum by immunoaffinity purification. A BLAST analysis was used to suggest cross-reactivity with IL-23 with Human and Mouse based on 100% homology with the immunizing sequence. Cross-reactivity with IL-23 from other sources has not been determined.
Relevant Links:	• NCBI - AAH66268 • UniProtKB - Q9NPF7 • GeneID - 51561

Application Details

Tested Applications:	ELISA, IF, IHC, WB
Application Note:	Anti-IL-23 Antibody is tested for use in E, WB, IF, IHC, and ICC. Expect a band approximately ~20.7 kDa on specific lysates. Western Blot, Immunocytochemistry, Immunofluorescence and Immunohistochemistry tested in human samples. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
IHC:	5µg/mL
WB:	1-4µg/mL

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.02% (w/v) Sodium Azide
Stabilizer:	None


Shipping & Handling

Shipping Condition:	Dry Ice
----------------------------	---------

Storage Condition: Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Expiration: Expiration date is one (1) year from date of receipt.

Images



Immunofluorescence Microscopy


Immunofluorescence Validation of IL-23.

Tissue: Human Pancreas Tissue.

Fixation: 4% paraformaldehyde-fixed.

Primary Antibody: Anti-IL-23 at 20 µg/mL.

Secondary Antibody: goat anti-rabbit IgG secondary antibody at 1:500 dilution (red) and DAPI staining (blue).



Immunofluorescence Microscopy


Immunofluorescence Validation of IL-23.

Cell: Raji Cells.

Fixation: 4% paraformaldehyde-fixed.

Primary Antibody: Anti-IL-23 at 20 µg/mL.

Secondary: goat anti-rabbit IgG secondary antibody at 1:500 dilution (red).



Immunohistochemistry

Immunohistochemistry Validation of IL-23.


Tissue: Human Pancreas Tissue.

Fixation: paraffin-embedded, formaldehyde and blocked with 10% serum for 1 h at RT.

Antigen retrieval: heat mediation with a citrate buffer (pH6).

Primary antibody: anti-IL-23 antibody at 5 µg/ml overnight at 4° C.

Secondary: goat anti-rabbit IgG H&L (HRP) at 1:250. Counter stained with Hematoxylin.



Immunocytochemistry

Immunocytochemistry of IL-23.


Cell: Raji cells.

Fixation: formaldehyde and blocked with 10% serum for 1 h at RT.

Antigen retrieval: heat mediation with a citrate buffer (pH6).

Primary Antibody: anti-IL-23 antibody at 10 µg/ml overnight at 4°C.

Secondary: goat anti-rabbit IgG H&L (HRP) at 1:250. Counter stained with Hematoxylin.




Western Blot

Western Blot Validation of IL-23.

Load: 15 µg of Human Raji Cell lysates per lane.

Primary antibody: anti-IL-23 at 1µg/mL in (Lane A: the absence of blocking peptide or Lane B: the presence of blocking peptide) for 1h at RT in 5% NFDN/TBST.

Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.




Western Blot

Western Blot Validation of IL-23.

Load: 20 µg of human lysates per lane. Lane 1: Daudi, Lane 2: K562, Lane 3: MCF7, Lane 4: THP-1.

Primary antibody: anti-IL-23 at 2µg/mL for 1h at RT in 5% NFDM/TBST.

Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.



Western Blot

Western Blot Validation of IL-23 with Recombinant Protein.

Load: 30 ng of human IL-23 recombinant protein.

Primary antibody: anti-IL-23 at 4µg/mL for 1h at RT in 5% NFDM/TBST.

Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.